Inflammatory injury in the lung or dermis occurring after systemic activation of complement or after local deposition of immune complexes is related to local activation of tissue macrophages and/or recruitment of blood neutrophils. While requirements for cytokines (IL-1, TNFa, MCP-1) vary with the model of injury, requirements for adhesion molecules (32 integrins, selectins, ICAM-1) differ. In most cases the immediate events related to tissue injury can be linked to toxic products from oxygen and L-arginine. Whether there is a single toxic product or a variety of toxic products remains to be determined. These data emphasize similarities and differences in the mechanisms of inflammatory injury, as a function of the inciting inflammatory agent and the organ system involved. -Environ Health Perspect 102(Suppl 10): 13-16 (1994) 
Introduction
Lung models of acute injury have been instructive about the complicated cascade of events leading to injury. In the models to be described, injury ensues as a result of recruitment and activation of inflammatory cells. In some cases blood leukocytes represent the exclusive source of toxic products. In other situations the toxic products are derived from a combination of residential phagocytic cells and recruited neutrophils. In yet another situation it appears that injury results exclusively from activation of residential phagocytic cells. The three models of acute lung injury (all in rats) are systemic activation of complement by cobra venom factor (CVF), intrapulmonary deposition of IgG immune complexes, and intrapulmonary deposition of IgA complexes. In all cases it appears that tissue injury is a result of oxidants generated from activated leukocytes and harmful effects of leukocyte-released proteases.
Lung Injury Produced by Systemic Activation of Complement third (C3) but not the fifth (C5) component of complement is insufficient to cause injury (2) . After infusion of CVF and activation of complement, intravascular activation of complement occurs, resulting in stimulation of blood neutrophils. The features of CVC-induced lung injury are . very rapid, early end point (30 min); * complement and neutrophil-dependent; . sensitive to catalase and deferroxamine; * independent of requirements for TNFa and IL-1; * dependent on CD1 la/CD 18 and CD lIb/CD18 and ICAM-1; . dependent on P-selectin and L-selectin but not E-selectin; * damage occurring at endothelial interface with neutrophils. The (12) . Pretreatment of animals with the iron chelator deferroxamine leads to a 53% reduction in lung injury whereas the iron-saturated form of this chelator is without effect (13) . These findings suggest the possibility of iron-dependent reduction of H202 that would result in production of 'OH, although this is a presumptive conclusion. There is also evidence that lung injury (16, 17) . These cytokines are functionally active, since their quantitation has been by employment of bioassays. Blocking of either cytokine leads to profound reduction in the neutrophil influx and reductions in the intensity of lung injury (16, 17 (8, 19) . Blocking of these selectins reduces injury (and neutrophil accumulation) by 95 and 33%, respectively. Blocking of P-selectin is without effect, even though the same intervention is highly protective in the CVF model of acute lung injury. The ultimate injury occurring after intrapulmonary deposition of IgG immune complex involves toxic products from both oxygen as well as Larginine, as described above. (19, 20) . Depletion of either complement or neutrophils reduces injury by 65 to 68% (Table 3) . One especially surprising finding has been that, while being highly protective against lung injury following deposition of the same IgG immune complexes, in the dermis the presence of catalase is without any protective effects, even though SOD is highly protective (21, 22) . This could suggest that dermal vascular endothelial cells are resistant to toxic oxygen products. Alternatively, the fact that SOD is highly protective in this model (reducing injury by 78%), and the finding that L-NMA is also significantly protective (23) , could suggest that the chief agent of injury is related to interactions of -NO with°2 to produce ONOO-, and ultimately, perhaps OH (see above). The protective effects of deferroxamine might be related to a recent observation that this (24) .
compound, being a potent iron chelator, can also react with ONOO* to bring about its chemical inactivation (14) . Recent studies have also demonstrated that IgG immune complex-induced dermal vasculitis requires IL-I but not TNFa (24) . This has been determined by the use of blocking antibodies, or by the use of TNFa receptor-I or IL-1 receptor antagonist. Immunohistochemical studies reveal the appearance of IL-1, but not TNFa, in interstitial cells within the dermis following immune complex deposition (24) . Why TNFa is not elaborated in the dermis under these conditions whereas in the lung there is abundant elaboration of both TNFa and IL-1 is unclear. Studies employing the intradermal coadministration of either TNFa or IL-1 with the anti-BSA have revealed that the recruitment of neutrophils and the expression of dermal vascular injury are both enhanced under such conditions (24) . This demonstrates that the dermal vasculature is indeed reactive to both cytokines. Whatever the details, it is clear that the pathophysiology of dermal vascular injury is different when compared to similar injury occurring in the lung.
IgA Immune Complex-induced Lung Injury
Features of IgA immune complex-induced lung injury are * injury peaks at 4 hr; * complement-dependent but neutrophilindependent; * requires products ofactivated pulmonary macrophages; * sensitive to catalase, SOD and deferroxamine; * requires L-arginine; * dependent on MCP-I but independent of TNFa and IL-1; * dependent on CD1I a/CD 1 8;
CDI lb/CD 18 and ICAM-1 * independent of requirements for L-, Eand P-selectins; * injury appears to be dependent on activated residential pulmonary macrophages. Injury in this model is induced by the intratracheal instillation of murine monoclonal IgGI anti-dinitrophenol (anti-DNP) followed by the intravenous infusion of DNP-BSA. Neutrophil depletion does not protect against injury, which is characterized by extensive injury of alveolar epithelial lining cells (25, 26) (Table 4 ). Very few neutrophils appear in BAL fluids or in tissue sections of lung. The injury seems to involve the activation of pulmonary macrophages by IgA immune complexes and complement activation products. IgA immune complexes alone seem insufficient to cause macrophage-mediated injury. The complement requirement probably relates to the need for opsonization of complexes and the generation of complement activation products, the combination with complexes leading to macrophage activation. Pulmonary injury in this model is highly susceptible to the protective effects of catalase, SOD, and deferroxamine (Table 4) . As expected, iron-saturated deferroxamine is without protective effects. There is compelling evidence in this model that toxic products from L-arginine play an important role, since the use of L-NMA leads to a high degree of protection (67%) (27) . With respect to cytokine requirements, very little TNFa and IL-I appear in the BAL fluids of these animals. Not surprising, antiTNFa or anti-IL-1 do not reduce the intensity of injury following (28) . In contrast, blocking of monocyte chemotactic protein (MCP-1) by antibody reduces IgG immune complex-induced lung injury significantly (approximately 80%) whereas this intervention in the IgG immune complex model of acute lung injury is without effect (29) . This sharply defines the requirement for cytokines in these two models of immune complex-induced lung injury. 32 integrin requirements in this model of injury demonstrate the involvement of both CDIIa/CD18 and CDIIb/CD18, and, as anticipated, the requirement for the "counter receptor" for these P2 integrins, ICAM-1 (27) . Since there appears to be little if any need for the recruitment of blood leukocytes into the lung in this model of injury, it is not surprising that the process appears to be independent of a requirement for any of the three selectins (8) . Taken together, these studies suggest that injury in this model is due to activation of residential intrapulmonary macrophages. Their activation probably requires involvement of CD11a/CD18 as well as CD11b/CD18, link all of these models, whether or not blood leukocyte recruitment is required, is the role of oxidants derived from oxygen as well as L-arginine. These toxic products appear to derive from phagocytic cells, either residential or recruited from the blood. A major problem at present is to define the patterns of differences (with respect to mediators required for injury) within the same organ and between organs, and to determine not only the chemical nature of the toxic oxidants but their targets as well. This information will assist in the development of therapeutic strategies designed to protect against harmful effects of the inflammatory response.
